

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): May 25, 2017

SECOND SIGHT MEDICAL PRODUCTS, INC.
(Exact Name of Registrant as Specified in Its Charter)

California

(State or Other Jurisdiction of Incorporation)

333-198073
(Commission File Number)

02-0692322
(IRS Employer Identification No.)

12744 San Fernando Road, Suite 400
Sylmar, California 91342

(Address of Principal Executive Offices)

(818) 833-5000
(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

ITEM 7.01. REGULATION FD DISCLOSURE

A copy of a slide presentation that Second Sight Medical Products, Inc. ("Second Sight ") intends to use during presentations made before groups and in hosting one-on-one meetings with individuals at the 18th Annual B. Riley Institutional Investor Conference in Santa Monica, California on May 25, 2017 (the "Presentation Materials"), is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference herein. The Presentation Materials speak as of the date of this Current Report on Form 8-K. While Second Sight may elect to update the Presentation Materials in the future or reflect events and circumstances occurring or existing after the date of this Current Report on Form 8-K, Second Sight specifically disclaims any obligation to do so. Additionally, Second Sight has posted the Presentation Materials on the Investor Relations section of Second Sight's website: <http://investors.secondsight.com>. The information contained in this Item 7.01 and Exhibit 99.1 hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by reference in such a filing.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

Exhibit No.	Description
99.1	Second Sight Medical Products, Inc. Investor Presentation dated May 2017

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 24, 2017

SECOND SIGHT MEDICAL PRODUCTS, INC.

/s/ Thomas B. Miller
By: Thomas B. Miller
Chief Financial Officer



A Better Way of Life for Patients

May 2017

Forward Looking Statements

NASDAQ:
EYES



This presentation contains certain forward-looking information about Second Sight that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. Words such as "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "strong," "up coming," and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding our ability to successfully develop and commercialize our products; our ability to expand our long-term business opportunities; financial projections and estimates and their underlying assumptions; and future performance.

In this document, we refer to information regarding potential markets for products and other industry data. We believe that all such information has been obtained from reliable sources that are customarily relied upon by companies in our industry. However, we have not independently verified any such information.


Forward-looking statements may address the following subjects among others: expected products, applications, customers, technologies and performance, coverage and insurance reimbursements, results of clinical studies, success of research and development and our expectations concerning our business strategy. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties referred to in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our Annual Report on Form 10-K as filed on March 16, 2017 and our other reports filed from time to time with the Securities and Exchange Commission. The audience is cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.



Our Mission

**enabling our
individuals to
achieve
greater
independence
& quality of
life with
implantable
visual
prosthetics**





Video: Bionic Eye Gives Sight to the Blind

NASDAQ:
EYES




<http://www.bloomberg.com/news/videos/2015-05-21/bionic-eyes-give-second-sight-to-the-blind>

Second Sight

Large Targeted Patient Population: 8+ Million

NASDAQ:
EYES




Second Sight

Second Sight ARGUS II Technology

NASDAQ:
EYES



Functional vision restored by bypassing the damaged part of the retina to send visual signals to the healthy retinal cells



- 1 Using a camera housed in a patient's glasses, images are collected and converted into a series of small electrical pulses.
- 2 These pulses are transmitted wirelessly to an electrode array on the surface of the retina.
- 3 These pulses stimulate the remaining cells in the retina, resulting in the perception of patterns of light in the brain.

Targeted Patient Populations for ARGUS II



400,000 legally blind worldwide from Retinitis Pigmentosa (RP)

RP is an inherited genetic disorder that causes peripheral vision loss. People with RP typically lose all functional vision by the age of 40 to 50.



2 million legally blind worldwide from Age-Related Macular Degeneration (AMD)


AMD causes loss of central vision and progresses to blindness.

Second Sight Orion I Technology

NASDAQ:
EYES



Functional vision restored by bypassing the damaged eye and/or optic nerve to send visual signals directly to the brain



- 1 Leverages ARGUS II technology.
- 2 Camera housed in a patient's glasses collects images and converts into a series of small electrical pulses
- 3 These pulses are transmitted wirelessly to an electrode array on the surface of the brain, bypassing the eye and the optic nerve.
- 4 These pulses stimulate the visual cortex, resulting in the perception of patterns of light in the brain.

Targeted Patient Populations for Orion I



Almost 6 million legally blind worldwide from other forms of untreatable blindness

Other diseases including glaucoma, diabetic retinopathy and eye trauma may render the eye or optic nerve nonfunctional and ultimately result in a complete loss of vision.

Second Sight



Pioneering Technology

United States Patent
Gregory et al.

Patent No. US 8,066,098 B2
Date of Patent: Aug 16, 2011

ABSTRACT
A method for providing a visual signal to a user of a visual prosthesis. The method includes: receiving a visual signal; processing the visual signal to generate a visual signal; and providing the visual signal to the user of the visual prosthesis.

CLAIMS
1. A method for providing a visual signal to a user of a visual prosthesis, the method comprising: receiving a visual signal; processing the visual signal to generate a visual signal; and providing the visual signal to the user of the visual prosthesis.

- Over 375 patents issued
- Over 125 patents pending

Groundbreaking Research

Five-Year Safety and Performance Results from the Argus II Retinal Prosthesis System Clinical Trial

Abstract
The Argus II Retinal Prosthesis System (RPS) is a retinal prosthesis system that provides visual information to blind and severely visually impaired individuals. The RPS consists of a video camera, a processor, and a retinal prosthesis. The RPS has been used in a clinical trial for five years. This report presents the results of the clinical trial, including safety and performance data.

Introduction
The Argus II Retinal Prosthesis System (RPS) is a retinal prosthesis system that provides visual information to blind and severely visually impaired individuals. The RPS consists of a video camera, a processor, and a retinal prosthesis. The RPS has been used in a clinical trial for five years. This report presents the results of the clinical trial, including safety and performance data.

- 75+ scientific publications
- 6 clinical & post-approval studies
- Demonstrated benefit out to ~10 years post-implant

Recognized Leadership

CNN
The CNN 10: Inventions of 2013

TIME
The 25 Best Inventions of 2013

POPULAR SCIENCE
2013 Innovation of the Year

NATIONAL GEOGRAPHIC
The End of Blindness
WINNING THE FIGHT TO SEE

Cleveland Clinic
Top Medical Innovation of 2014

WORLD ECONOMIC FORUM
Technology Pioneer 2014

50 SMARTEST COMPANIES
The 50 Smartest Companies for 2014

- Numerous innovation awards
- Coverage in all major countries and US media markets

Neurostimulation Emerges as First Effective Treatment for Blindness

NASDAQ:
EYES



Significant first mover advantage with 5+ year lead in the U.S.

Retinal Prosthesis Competitors	CE Mark	Widely Reimbursed in Europe	FDA Approved	Reimbursed in USA
Second Sight, Argus®II	✓	✓	✓	✓
Retina implant (Germany)	✓	✗	✗	✗
Pixium Vision (France)	✓	✗	✗	✗
Nidek Co., Ltd. (Japan)	✗	✗	✗	✗
NanoRetina (Israel)	✗	✗	✗	✗
BionicVision (Australia)	✗	✗	✗	✗
Other Therapies	CE Mark	Widely Reimbursed in Europe	FDA Approved	Reimbursed in USA
Stem Cells	✗	✗	✗	✗
Gene Therapy	✗	✗	✗	✗
Opto-Genetics	✗	✗	✗	✗
Transplant	✗	✗	✗	✗

Second Sight



Achievements-to-Date

What's Next?



- 5 of 12 MAC* jurisdictions (~40% of US population) with positive coverage decision
- Attained new CPT codes for initial programming and reprogramming of Argus II
- \$150k reimbursement rate set for 2017

- Continue coverage expansion to remaining MAC jurisdictions
- Maintain high success rate of prior authorization approvals for Medicare Advantage & commercial patients




- Coverage in England under "Commissioning through Evaluation" program
- Coverage in Germany under NUB (Innovation funding) program
- Coverage in France under "Forfait Innovation" program
- Reimbursement in one region of Italy

- Enroll 10 patent post-market study in UK under Commissioning through Evaluation (CtE) program
- Inclusion in standard payment system in France
- Pursuing reimbursement in Belgium and Turkey
- Pursuing reimbursement in additional regions of Italy

Goal: to offer Argus II to more patients/candidates worldwide



Building a Foundation for Long-Term Growth




Strengthening Centers of Excellence

NASDAQ:
EYES



Goal

Partner with leading medical institutions to establish a network of high-quality surgical centers that are capable of treating a higher volume of patients



Second Sight

Treating Better-Sighted Patients with Argus II Enhancements

NASDAQ:
EYES



Clinical Testing of Current Argus II Technology in Better-Sighted RP Patients

Clinical Testing of Argus II Enhancements in Better-Sighted RP & AMD Patients

- New external components for streamlined appearance
- Software improvements for advanced image processing
- Improved retinal stimulation



Second Sight

Expanding into Potential 5.8M Patient Market with Orion I


NASDAQ:
EYES



Leverage existing Argus II technology



Bypass the optic nerve and directly stimulate the visual cortex



Animal implants explanted & histology complete



First in human feasibility assessment complete (n=1) with positive outcomes



Begin US feasibility study in 2017

- 30 year old female patient
- Neuropace RNS System (*approved to treat epilepsy*)
- Eight electrodes implanted
- Results showed each electrode generated a perceptible spot of light
- No serious adverse events

Second Sight Select Financials

NASDAQ:
EYES



(USD \$ in Thousands)	Q1 2017	Q1 2016	FY 2016	FY 2015
Implants	14	10	42	75
Revenue	\$1,009	\$1,053	\$3,985	\$8,950
Gross Profit (Loss)	(118)	141	(6,091)	3,657
Net Loss	(7,548)	(5,816)	(33,179)	(20,018)
Non-GAAP Adjusted Net Loss*	(7,280)	(4,870)	(24,812)	(17,007)

(USD \$ in Thousands)	Mar 31, 2017	Dec 31, 2016	Dec 31, 2015
Cash, cash equivalents & investments	\$24,387	\$10,875	\$15,960
Outstanding Debt	\$0	\$0	\$0

*Non-GAAP adjusted net loss excludes non-cash expenses including stock-based compensation and reserve for excess inventory.

A Better Way of Life for Patients

NASDAQ:
EYES



Improved Orientation
and Mobility

Significant
Improvement in
Quality of Life



Greater Independence

Enhanced Connection
to Loved Ones

Second Sight



Technology Leadership

- First and only treatment approved for sale in the US, EU, Saudi Arabia, Turkey and Canada
- Robust IP portfolio with 500+ patents issued and pending
- Significant first mover advantage with 5+ year lead over any other therapeutic option in US

Large Market Opportunity

- RP, AMD and other untreatable forms of blindness totaling an estimated 8-plus million people
- Significant unmet clinical need with proven clinical benefit

Increased Adoption of Argus II in 2017

- Centers of Excellence commercial model
- Technology enhancements to broaden RP target to better-sighted patients

Established Reimbursement in US and Europe

- 2017 established rate of \$150k in US with coverage in 17 states
- CPT codes to be established (July 1, 2017) for post-surgery programming
- Reimbursed in Germany, Italy, France and UK

Robust R&D pipeline

- Argus II improvements to advance performance and expand markets
- Orion I for nearly all untreatable forms of blindness ready for clinical study in 2017



Second Sight Medical Products, Inc.

12744 San Fernando Road

Suite 400

Sylmar, CA 91342

Main: 818-833-5000

www.secondsight.com

Will McGuire

President & CEO

Direct: 818-833-5040

wmcguire@secondsight.com

Retail Investor Relations

Greg Falesnik

Managing Director

MZ North America

Direct: 949-385-6449

Greg.Falesnik@mzgroup.us

Institutional Investor Relations

Lisa Wilson

President

In-Site Communications, Inc.

Direct: 212-452-2793

lwilson@insitecony.com